208 related articles for article (PubMed ID: 30775033)
1. Are there any theranostic biomarkers in small cell lung carcinoma?
Pezzuto F; Fortarezza F; Lunardi F; Calabrese F
J Thorac Dis; 2019 Jan; 11(Suppl 1):S102-S112. PubMed ID: 30775033
[TBL] [Abstract][Full Text] [Related]
2. Personalized Therapy of Small Cell Lung Cancer.
Schneider BJ; Kalemkerian GP
Adv Exp Med Biol; 2016; 890():149-74. PubMed ID: 26703804
[TBL] [Abstract][Full Text] [Related]
3. Prospects of targeted and immune therapies in SCLC.
Hendriks LEL; Menis J; Reck M
Expert Rev Anticancer Ther; 2019 Feb; 19(2):151-167. PubMed ID: 30590971
[No Abstract] [Full Text] [Related]
4. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
5. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
6. Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer.
Fujii K; Miyata Y; Takahashi I; Koizumi H; Saji H; Hoshikawa M; Takagi M; Nishimura T; Nakamura H
Proteomics Clin Appl; 2018 Nov; 12(6):e1800015. PubMed ID: 29888431
[TBL] [Abstract][Full Text] [Related]
7. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
8. Progress and challenges in the treatment of small cell lung cancer.
Tartarone A; Giordano P; Lerose R; Rodriquenz MG; Conca R; Aieta M
Med Oncol; 2017 Jun; 34(6):110. PubMed ID: 28456992
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
10. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
11. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.
Meder L; König K; Fassunke J; Ozretić L; Wolf J; Merkelbach-Bruse S; Heukamp LC; Buettner R
Exp Mol Pathol; 2015 Dec; 99(3):682-6. PubMed ID: 26546837
[TBL] [Abstract][Full Text] [Related]
12. Identification of Small and Non-Small Cell Lung Cancer Markers in Peripheral Blood Using Cytokinesis-Blocked Micronucleus and Spectral Karyotyping Assays.
El-Zein RA; Abdel-Rahman S; Santee KJ; Yu R; Shete S
Cytogenet Genome Res; 2017; 152(3):122-131. PubMed ID: 28898877
[TBL] [Abstract][Full Text] [Related]
13. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
[TBL] [Abstract][Full Text] [Related]
14. [Biology of small-cell bronchogenic carcinoma: recent advances].
Levy R; Andrieu JM; Even P
Bull Cancer; 1992; 79(1):25-46. PubMed ID: 1325850
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.
Stumpf C; Kaemmerer D; Neubauer E; Sänger J; Schulz S; Lupp A
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1921-1932. PubMed ID: 30076481
[TBL] [Abstract][Full Text] [Related]
16. Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer.
Hong X; Cui B; Wang M; Yang Z; Wang L; Xu Q
Tohoku J Exp Med; 2015 Aug; 236(4):297-304. PubMed ID: 26250537
[TBL] [Abstract][Full Text] [Related]
17. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects.
Demedts IK; Vermaelen KY; van Meerbeeck JP
Eur Respir J; 2010 Jan; 35(1):202-15. PubMed ID: 20044461
[TBL] [Abstract][Full Text] [Related]
18. Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas.
Desrichard A; Kuo F; Chowell D; Lee KW; Riaz N; Wong RJ; Chan TA; Morris LGT
J Natl Cancer Inst; 2018 Dec; 110(12):1386-1392. PubMed ID: 29659925
[TBL] [Abstract][Full Text] [Related]
19. Basic science of small cell lung cancer.
Williams CL
Chest Surg Clin N Am; 1997 Feb; 7(1):1-19. PubMed ID: 9001753
[TBL] [Abstract][Full Text] [Related]
20. Small cell lung cancer: etiology, biology, clinical features, staging, and treatment.
Cook RM; Miller YE; Bunn PA
Curr Probl Cancer; 1993; 17(2):69-141. PubMed ID: 8395998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
